Bio Green Med Solution (BGMS)
NASDAQ:BGMS
Want to see BGMS full AI Analyst Report?
BGMS Stock Chart & Stats
$1.45
--
Market closed
$1.45
--
Day’s Range― - ―
52-Week Range$0.73 - $100.67
Previous CloseN/A
VolumeN/A
Average Volume (3M)473.94K
Market Cap
$5.74M
Enterprise Value-$1.23M
Total Cash (Recent Filing)$3.50M
Total Debt (Recent Filing)$2.00K
Price to Earnings (P/E)―
Beta0.57
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield10.27%
Share Statistics
EPS (TTM)-2.21
Shares Outstanding5,519,456
10 Day Avg. Volume1,252,948
30 Day Avg. Volume473,939
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.47
Price to Sales (P/S)4.33
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.21
Enterprise Value/Revenue-1.65
Enterprise Value/Gross Profit-8.99
Enterprise Value/Ebitda0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-268.8
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Strategic Business Pivot & Early RevenueThe company exited legacy biopharma and shifted to fire safety distribution via the Fitters acquisition, which produced $0.7M in 2025. This pivot lowers R&D intensity, creates a clearer commercial revenue path, and aligns operations to a distributable product model that can scale with sales focus.
Low Leverage And Reported EquityThe balance sheet shows minimal 2025 debt and $6.84M equity, providing financial flexibility. Lower leverage reduces refinancing and interest risks, enabling the firm to sustain operations or fund strategic moves while pursuing revenue growth before profitability is achieved.
Preference For Servicing Preferred CapitalThe board declared a preferred dividend, indicating a priority to service preferred obligations and a degree of cash discipline. For income-focused stakeholders, regular preferred payouts suggest management is managing cash allocation and maintaining investor relations around fixed-cost capital.
Bears Say
Persistent Negative Cash FlowConsistently negative operating and free cash flow (2023-2025) implies ongoing cash burn and reliance on external financing. This constrains runway, raises dilution or financing risk, and limits the company's ability to invest in growth or absorb shocks until it achieves sustained positive cash generation.
Multi-Year Operating LossesThe company has posted sizable operating losses across years, with limited operating leverage despite revenue rebound. Persistent negative EBIT and historical large losses hinder reinvestment capacity, jeopardize sustainable profitability, and make long-term scaling dependent on structural margin improvement or further strategic change.
Preferred Stock Delisting RiskNasdaq delisting of the preferred shares shifts liquidity to OTC and signals market compliance issues for that instrument. Reduced liquidity and market profile can increase cost of capital for preferred holders, complicate future financings and weaken investor confidence in the company’s capital structure.
Bio Green Med Solution News
BGMS FAQ
What was Bio Green Med Solution’s price range in the past 12 months?
Bio Green Med Solution lowest stock price was $0.73 and its highest was $100.67 in the past 12 months.
What is Bio Green Med Solution’s market cap?
Bio Green Med Solution’s market cap is $5.74M.
When is Bio Green Med Solution’s upcoming earnings report date?
Bio Green Med Solution’s upcoming earnings report date is May 13, 2026 which is in 27 days.
How were Bio Green Med Solution’s earnings last quarter?
Bio Green Med Solution released its earnings results on Mar 30, 2026. The company reported -$2.21 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.21.
Is Bio Green Med Solution overvalued?
According to Wall Street analysts Bio Green Med Solution’s price is currently Overvalued.
Does Bio Green Med Solution pay dividends?
Bio Green Med Solution pays a Notavailable dividend of $0.15 which represents an annual dividend yield of 10.27%. See more information on Bio Green Med Solution dividends here
What is Bio Green Med Solution’s EPS estimate?
Bio Green Med Solution’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio Green Med Solution have?
Bio Green Med Solution has 5,519,456 shares outstanding.
What happened to Bio Green Med Solution’s price movement after its last earnings report?
Bio Green Med Solution reported an EPS of -$2.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.842%.
Which hedge fund is a major shareholder of Bio Green Med Solution?
Currently, no hedge funds are holding shares in BGMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio Green Med Solution
A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Rein Therapeutics
―
Bluejay Diagnostics
―
Neuphoria Therapeutics
―
Ownership Overview
64.26% Insiders
<0.01% Mutual Funds
1.08% Other Institutional Investors
34.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---